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Primer
I
n the decade since human genes associated with 
neurodegenerative disease were first used in flies to 
create pathological phenotypes [1–5], a minor industry 
has sprung up using flies as a model to study the mechanisms 
underlying central nervous system malfunction in humans. 
Why study neurodegeneration in flies? Their small size, rapid 
generation time, and low costs for maintenance as compared 
to mammalian models make them attractive enough. The 
true value of flies to the study of neurodegenerative disorders, 
however, is their capacity to provide a platform for unbiased 
genetic screens to identify components of pathological 
pathways. If expression of pathological human genes in the 
fly successfully generates an abnormal phenotype, such as 
slowed motor activity or degeneration of the retina, this 
phenotype can then be used in conjunction with the rich 
genetic toolbox that Drosophila researchers have developed 
over the last 90 years to identify pathways that contribute to 
this degeneration. This approach is unbiased, i.e., it does 
not depend upon prior assumptions about mechanisms 
underlying disease, and genome-wide screens can be carried 
out in the fly that would be difficult if not impossible to carry 
out using mouse models. 
Key to such an approach is how similar flies are to humans. 
A stunning 75% (approximately) of the genes implicated 
in human genetic disorders have at least one homolog in 
the fruit fly (see http://superfly.ucsd.edu/homophila/ 
for further information). In general, fundamental aspects 
of cell biology relevant to processes as diverse as cell cycle 
regulation, synaptogenesis, membrane trafficking, and cell 
death are similar in Drosophila and humans. Of course, there 
are important differences between flies and humans; for 
example, the circulatory system is much simpler in the fly, 
and cognitive processes are much less complex. Nonetheless, 
the fly has proved itself as a useful adjunct to mammalian 
models for neurodegenerative diseases.
A variety of neurodegenerative disorders have been 
modeled in the fly (for reviews, see [6–10]); perhaps the best 
established and most robust models are those associated with 
a group of inherited disorders that are all caused by the same 
mechanism: expansion of an unstable CAG repeat resulting 
in expression of proteins containing expanded polyglutamine 
tracts. The best known of these disorders is Huntington 
disease, but there are a number of somewhat similar disorders 
also caused by a CAG repeat expansion that are collectively 
referred to as the spinocerebellar ataxias (SCAs). These 
are generally adult-onset, progressive neurodegenerative 
disorders that feature impaired coordination due to 
degeneration of the cerebellum [11]. The different SCAs 
may have slightly different symptoms in addition to impaired 
coordination, such as tremor in SCA type 2 (SCA2) similar 
to that seen in Parkinson disease or muscular atrophy due 
to nerve damage in SCA3, but all are inexorably progressive. 
Some symptoms, such as impaired swallowing or gait ataxias, 
may be mildly improved by medications, assistive devices, or 
physical therapy, but no disease-modifying treatments exist. 
The proteins in which the polyglutamine expansions occur in 
each disorder show no obvious similarities and are referred to 
as ataxins 1, 2, 3, etc. (Atx1, Atx2, Atx3, etc.).
Although the syndromic classifications of 
neurodegenerative disorders that began to be developed 
in the nineteenth century focused on distinctions between 
different disorders, more recent pathological and molecular 
analyses have begun to identify commonalities between 
what have traditionally been thought of as distinct diseases, 
as well as crosstalk between seemingly unrelated disease-
associated proteins. In this issue of PLoS Biology, Derek 
Lessing and Nancy Bonini describe an interaction in which 
Atx2 contributes to the pathogenicity of Atx3 [12]. This 
report comes on the heels of similar work by Juan Botas 
and colleagues describing an interaction between Atx2 and 
Atx1 [13]. Here, I set out to demystify the creation and 
deployment of fly models of neurodegenerative diseases, and 
to put the current studies of interaction among ataxins in 
perspective. 
How and Why Are Human Disease-Associated Genes 
Expressed in the Fly? 
The most common means of expressing human 
neurodegenerative genes in Drosophila makes use of the 
binary GAL4-dependent upstream activating sequence 
(GAL4/UAS) system [14] (Figure 1). The gene of interest 
is subcloned into the UAS expression construct (Figure 
1B), which is microinjected into fly embryos to establish 
transgenic lines. Once these lines are in hand, disease 
genes can be expressed in a variety of tissues using available 
stocks that express the yeast transcriptional co-activator 
GAL4. One of the most useful of these driver lines [15] 
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expresses GAL4 in all cells of the eye under control of 
the glass transcription factor (Figure 1A). The fly eye is 
particularly useful in the context of genetic screens for 
genes that affect tissue integrity, as fertility is retained 
even in the presence of severe retinal degeneration. So in 
order to achieve expression of a human SCA gene, one 
can simply take the new flies that have been generated 
containing the human cDNA (Figure 1B) and cross them 
with an already established strain of flies that express GAL4 
in the retina (Figure 1A). Both transgenes will be expressed 
in the progeny of these flies (Figure 1A and Figure 1B); 
thus when GAL4 protein is expressed under control of the 
endogenous glass promoter, it will activate expression of the 
SCA transgene.
Genetic screens using the fly eye have been enormously 
successful in the study of neurodegeneration. The compound 
eye of Drosophila melanogaster is composed of some 800 
repeating subunits, called ommatidia (Figure 2A). Each 
ommatidium contains eight photoreceptor neurons, seven 
of which are visible in tangential sections taken toward the 
external surface of the eye (Figure 2B). Each photoreceptor 
elaborates a membranous organelle, called a rhabdomere, 
which is involved in phototransduction. In Figure 2B, actin 
in the rhabdomeres has been stained with fluorescently 
labeled phalloidin. Degeneration of photoreceptor neurons 
can be quantitated by counting the rhabdomeres in each 
ommatidium, using an optical neutralization technique 
(often referred to as the “pseudopupil”) to obtain images 
similar to that in Figure 2B. This technique is rapid, 
reproducible, does not require staining using antibodies or 
dyes, and has been used with great success since it was first 
introduced in studies of human neurodegenerative diseases 
almost ten years ago [2].
How Are Fly Models Used in Unbiased Genetic 
Screens?
Once a UAS line encoding a pathogenic gene (e.g., expanded 
Atx3; Figure 1B) has been established, it can be stably placed 
in a combination with a driver line such as glass multimer 
reporter (GMR)-GAL4 (Figure 1A). This stabilized stock is 
now ready for use in genetic screens that employ transposon 
or deletion libraries. One of the most commonly used 
transposon libraries utilizes the enhancer–promoter (EP) 
element (Figure 1C), which is essentially an “empty” UAS 
construct that drives expression of nearby genomic sequences 
in the presence of GAL4 [16]. What this means in practical 
terms is that a large number of crosses can be set up with a 
tester strain that contains the driver line (“A”) and the UAS 
line (“B”). These flies are then crossed with a large number 
of individually derived stocks that contain insertions of this 
EP in different regions of the genome. The progeny of these 
crosses will then contain three different transgenes: the GAL4 
driver (A), the UAS lines (B), and an EP insertion. In these 
crosses, the GAL4 will not only drive expression of the SCA 
gene, but will also drive expression of endogenous fly genes 
in the vicinity of the EP insertion. In a subset of these crosses 
(A + B + C), the eye phenotype may be either more or less 
severe than in the control cross (A + B only); one can then 
infer that the target gene in the vicinity of the EP insertion 
in C is a player in the pathological process set in motion by 
expression of the pathological SCA gene. 
A Tale of Two Ataxins
One of the genetic modifiers identified in the work described 
by Lessing and Bonini in this issue corresponded to the 
endogenous fly version of Atx2 (dAtx2): the rough eye 
phenotype produced by mutant human Atx3 was stronger in 
the presence of gain-of-function dAtx2 alleles. Leo Pallanck 
and colleagues had previously characterized this gene [17], 
and the enhancement of the Atx3 phenotype was confirmed 
using directed overexpression of dAtx2 (i.e., UAS-dAtx). 
Retinal phenotypes are certainly useful for identifying 
genetic modifiers of disease; however, retinal degeneration 
is not a prominent feature of the SCAs (with the notable 
exceptions of SCA2 [18] and SCA7 [19]). Nonetheless, 
because the retina can easily be viewed by dissecting 
microscope and can be dramatically disrupted without 
compromising the overall health of the fly, eye phenotypes 
are propitious for genetic screens. Of course, one would 
like to see new genes identified with the retina to be studied 
further in other tissues that may be more characteristically 
affected in neurodegenerative disorders, such as brain or 
muscle. Overexpression of dAtx2 alone using the GMR-GAL4 
driver produced abnormal eye phenotypes [17]. Given that 
the SCAs are adult-onset disorders, there is understandable 
bias in the field against models that rely exclusively on 
developmental phenotypes. In addition, although the 
mechanisms underlying adult-onset cell death may be quite 
similar to those that take place in developmental apoptosis 
in some instances, this may not hold true in others. For these 
reasons, the authors turned to a later-onset retinal driver, 
rhodopsin-1 [20]. This driver generates expression shortly 
before emergence of the adult fly in the outer photoreceptors 
(R1–R6 in Figure 2B), and has been used successfully in 
prior studies of polyglutamine modifiers [21]. Quantitative 
analysis of images obtained using optical neutralization 
doi:10.1371/journal.pbio.0060053.g001
Figure 1. Schema for Generation of Fly Models of 
Neurodegenerative Diseases
A variety of driver lines are available that express the yeast transcriptional 
co-activator GAL4; shown is GMR-GAL4, which uses regulatory DNA that 
responds to the glass transcription factor to induce expression of GAL4 
in all cells of the eye beginning in larvae (A). The cDNAs encoding human 
disease-associated genes, such as that for Atx3, which causes SCA3, are 
subcloned into the UAS expression construct (B) and used to generate 
transgenic flies. When these flies (B) are crossed with those of a driver 
line (A), GAL4 is expressed in the progeny and induces expression of the 
disease gene, producing an abnormal eye phenotype that can readily 
be scored under the dissection microscope. A stable tester stock can be 
established that expresses both of these transgenes and used to carry 
out genetic screens. In the case of the EP element (C), in the presence 
of GMR-GAL4 (A), genomic sequences near the EP element can be 
identified that modulate severity of the tester stock. PLoS Biology  |  www.plosbiology.org PLoS Biology  |  www.plosbiology.org 0238 February 2008  |  Volume 6  |  Issue 2  |  e53
confirmed the genetic interaction of overexpressed Atx3 and 
dAtx2; conversely, loss-of-function alleles of dAtx2 suppressed 
mutant Atx3-induced phenotypes.
Modifier validation is often carried out in other neuronal 
populations in addition to the retina. This can be challenging 
to carry out in the central nervous system due to technical 
difficulties with quantitation using pan-neuronal drivers. 
Lessing and Bonini turned to sensory neurons in the wing 
margin and made clever use of the MARCM (mosaic analysis 
with a repressible cell marker) [22] technique to generate 
clones that were mutant for two copies of dAtx2. Using 
this technique, fluorescent Atx3-expressing neurons were 
quantitated in living flies; these again highlighted a dosage-
sensitive role of dAtx2 in contributing to neurodegeneration 
caused by mutant Atx3. 
Given that a variety of lines expressing human 
neurodegenerative disease genes are available, one simple 
means of assessing the specificity of a genetic interaction is by 
comparing modifier effects in the context of other proteins. 
This was of particular interest in the case of the Atx2/Atx3 
interaction, given that Atx2 had previously been identified 
as a modifier of Atx1. Enhancement of the polyglutamine 
phenotypes also was observed with an exon-1 Huntingtin 
construct [23], but not a larger fragment [24], indicating 
some importance of protein context in the interaction. 
These data are complemented by those reported by Botas 
and colleagues, who used a mutant Huntingtin construct 
intermediate in length between the two used by Bonini and 
Lessing; this Huntingtin phenotype also was not modified by 
dAtx2. 
Human Atx2 is unusual among the ataxins in that it is 
almost exclusively a cytoplasmic protein, although it has 
been identified in nuclear inclusions in SCA3 post-mortem 
brain [25]. Immunohistochemical and western blot data 
provided by Lessing and Bonini suggested a role for Atx2 
in regulating aggregation of mutant Atx3, and a construct 
lacking the PAM2 motif (PABP-interacting motif 2) of Atx2 
was incapable of providing enhancement. Endogenous dAtx2 
was recruited into inclusions. This finding mirrors that of 
Botas and colleagues in PLoS Genetics, who in addition showed 
that forced nuclear expression of dAtx2 enhanced its toxicity 
[13]. The PAM2 motif of Atx2 mediates its interaction with 
poly(A)-binding protein (PABP), and the Atx3 phenotype was 
sensitive to PABP dosage.
Quo Vadis, Ataxia?
This work is basic research; thus neither the work of 
Lessing and Bonini nor that recently reported by Botas and 
colleagues, unfortunately, has identified a magic bullet for 
treatment of inherited ataxias or related polyglutamine 
disorders. They do suggest however that important 
interactions may exist between disease-associated proteins 
that have traditionally been associated strictly with single 
diseases. Importantly, this crosstalk suggests that a cure for 
one may be a cure for all. Analogous to the crosstalk that 
may take place between pathogenic fragments of amyloid 
precursor protein and tau in the context of Alzheimer 
disease [26], further study of interactions between ataxins 
may provide important mechanistic insights into disease 
pathogenesis. If Atx2 does indeed play a role in amplifying 
toxicity of both Atx1 and Atx3, then perhaps dampening of 
this activity by genetic or pharmacological means could lead 
to a disease-modifying as opposed to a purely symptomatic 
treatment. 
Could effecting small changes in the toxicity of mutant 
Atx3 by genetic or pharmacological means make a difference 
in the lives of patients? Age of onset for polyglutamine 
repeat disorders is not determined exclusively by length of 
the repeat expansion, and both genetic and environmental 
factors are likely to play a role in disease onset and 
progression. Even minor decreases in mutant protein toxicity 
might be translated as major improvements in quality of life 
for those afflicted with these incurable disorders. 
Thus the simple fruit fly has been used to rapidly 
and readily screen through a large number of potential 
interacting genes to uncover a surprising and potentially 
therapeutically important interaction between two genes that 
previously had not been known to interact or share common 
features, apart from a polyglutamine tract. The beauty of 
this sort of work is that even a small group with limited 
resources can carry it out using fly models. The next step, 
obviously, will be to further analyze this interaction using 
mammalian models. Will a mouse that expresses mutant Atx3 
develop more severe neurodegeneration when it is crossed 
with one that overexpresses normal Atx2? These and similar 
experiments will be key steps in further investigating the 
significance of the findings described by Lessing and Bonini. 
Given that previous insights into neurodegeneration learned 
from Drosophila, such as chaperone and histone deacetylase 
inhibitor rescue [6–9], have translated to mammalian models, 
this tale of two ataxins provides a launching ground to take 
these new findings from fly to mouse and ultimately to 
human patients. ◼
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